CRGX stock icon

CARGO Therapeutics

18.47 USD
+1.36
7.95%
At close Dec 6, 4:00 PM EST
After hours
18.47
+0.00
0.00%
1 day
7.95%
5 days
2.10%
1 month
-13.16%
3 months
-2.02%
6 months
2.67%
Year to date
-18.71%
1 year
24.29%
5 years
27.12%
10 years
27.12%
 

About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Employees: 170

0
Funds holding %
of 6,794 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

217% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 12

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

21% more capital invested

Capital invested by funds: $717M [Q2] → $865M (+$148M) [Q3]

8% more funds holding

Funds holding: 73 [Q2] → 79 (+6) [Q3]

6.77% more ownership

Funds ownership: 95.19% [Q2] → 101.96% (+6.77%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$28
52%
upside
Avg. target
$31
65%
upside
High target
$33
79%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
36% 1-year accuracy
43 / 120 met price target
79%upside
$33
Buy
Reiterated
15 Nov 2024
Chardan Capital
Geulah Livshits
31% 1-year accuracy
11 / 35 met price target
52%upside
$28
Buy
Maintained
13 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
Positive
The Motley Fool
3 months ago
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
Neutral
GlobeNewsWire
3 months ago
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
6 months ago
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
Neutral
InvestorPlace
6 months ago
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren't the breakout stocks that can deliver significant returns.
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
Neutral
GlobeNewsWire
6 months ago
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
6 months ago
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
– Financing includes participation from new and existing investors –  – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses.
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
Positive
Zacks Investment Research
6 months ago
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
Positive
Zacks Investment Research
6 months ago
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
Charts implemented using Lightweight Charts™